





To the Editor: In January 2013, 
a 34-year-old man was admitted be-
cause of severe shock to the intensive 
care unit (ICU) at University Hospital 
of Liege (Liege, Belgium) on day 10 
after nonfamilial hematopoietic stem 
cell transplantation (HSCT). X-linked 
gp91phox gene mutation chronic 
granulomatous disease (CGD) had 
been diagnosed when he was 4 years 
of age. The patient had a history of 
recurrent pulmonary aspergillosis 
(Aspergillus fumigatus infection) and 
anaphylaxis to lipid-based formula-
tions of amphotericin B (AmB). Dur-
ing the year before HSCT, he had 
received voriconazole for possible 
recurrent aspergillosis until 2 cavitary 
necrotic pulmonary lesions prompted 
prolonged combined treatment with 
caspofungin. No fungus was yielded 
before transplant. 
On day 9 after HSCT, a com-
puted tomographic (CT) scan of the 
abdomen showed multiple hypodense 
lesions in the hepato-splenic paren-
chyma, and the patient was admitted 
to the ICU. Antifungal drug adminis-
tration were escalated (voriconazole 
6 mg/kg twice daily, caspofungin 70 
mg/day), taking into account patient’s 
history of anaphylaxis. The patient re-
covered from aplasia within 12 days 
(1), and CT-guided liver biopsy was 
performed on day 20 after HSCT.
Microbiological cultures of the 
liver biopsy sample were performed 
on 5% sheep blood agar and Sab-
ouraud agar medium supplemented 
with chloramphenicol. The plates 
were incubated at 30°C and 37°C, 
respectively, for 10 days. Subcul-
tures were performed on malt agar, 
Takashio, and agar-agar medium and 
incubated at 30°C, 37°C, and 42°C, 
respectively, to obtain sporulation. 
Blood cultures were collected on the 
same day the biopsy was performed 
on BacT/ALERT FAN aerobic and 
anaerobic medium bottles (bioMéri-
eux, Durham, NC, USA). Antifungal 
susceptibility testing was performed 
by Etest. Histopathologic examination 
was conducted after the liver sections 
were stained with hematoxylin and eo-
sin, periodic acid–Schiff, and Gomori 
methenamine silver.
We sequenced regions of inter-
nal transcribed spacers (ITS) 1 and 2 
of the rRNA genes (2).The ribosomal 
target of the large subunit RNA gene 
(D1–D2 region) was used to con-
firm the first results. Sequences were 
aligned by using the GeneStudio Pro 
software (http://genestudio.com/) and 
identified in BLAST (http://blast.ncbi.
nlm.nih.gov/Blast.cgi) and in the CBS 
database for filamentous fungi (http://
www.cbs.knaw.nl/collections/Biolo-
MICSSequences.aspx).
Histologic examination of the liv-
er biopsy sample showed fungal fila-
ments of variable diameter, without 
septa, and with bulbous dilations sug-
gesting mucormycosis amid necrotic 
parenchyma (Figure). A white fila-
mentous mold grew after the sample 
was incubated for 2 days on Sabouraud 
agar at 30°C and 5% sheep blood agar 
medium at 37°C. Microscopic exami-
nation of the culture confirmed a fun-
gus belonging to the mucoromycotina. 
Nonseptate hyphae of irregular width 
were visible and marked by short lat-
eral extensions distributed at right 
angles along the filaments. Despite 
subcultures on different media and 
incubation at 30°C, 37°C, and 42°C, 
no sporulation was observed. The fun-
gus did not grow on Sabouraud agar 
supplemented with cycloheximide. 
One blood culture was positive after 3 
days’ incubation at 37°C, and the sub-
culture grew the same fungus. In vi-
tro susceptibility testing showed high 
MICs (>32 mg/L) for voriconazole 
and caspofungin and lower MICs 
for AmB (1 mg/L) and posaconazole 
(0.012 mg/L). The 3 targeted sequenc-
es of ITS2 alone (GenBank accession 
no. KJ825897), ITS1–ITS2 (GenBank 
accession no. KJ82598), and D1–D2 
region of the rRNA genes (GenBank 
accession no. KJ825899) identified 
Mortierella wolfii with 98% and 100% 
similarity with the reference sequenc-
es in the CBS database.
CGD is a primary immunode-
ficiency syndrome characterized by 
impaired phagocytic activity of in-
tracellular pathogens and fungi. In-
vasive fungal infections account for 
one third of deaths attributed to CGD, 
and lung involvement is predominant 
(3). To our knowledge, the 2 reports 
of human cutaneous infection with 
M. wolfii are considered inconclusive 
(4). It is a mold belonging to the order 
Mortierellales according to the most 
recent taxonomy (5) and is consid-
ered a pathogen solely of animals. 
It causes abortion, encephalitis, and 
pneumonia in cattle in specific geo-
graphic locations (Australia, North 
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America, and Japan) (6). The natural 
habitats of M. wolfii include moldy 
grass in silage, and infected animals 
might inhale spores from contami-
nated silage or acquire them through 
digestive tract ulcerations after in-
gestion of semen (4). Thus, possible 
transmission routes of Mortierella 
sp. in this patient include airborne 
exposure to mulch or ingestion of 
contaminated imported food during 
pressure-selection azole prophylaxis 
and inflammatory bowel disease. 
After being ingested or inhaled, this 
weakly virulent mold must have re-
mained quiescent until a few months 
before HSCT. We suspect that it was 
responsible for the necrotic cavitary 
pneumonia for which no fungus was 
identified before transplant. M. wolfii 
eventually emerged during a pro-
found iatrogenic neutropenic period 
(1). Because death partly correlates 
with dissemination, preemptive and 
adequate antifungal treatment is of 
utmost importance in mucormyco-
sis. In this patient, who died 11 days 
after ICU admission, past anaphy-
laxis precluded prompt initiation of 
a lipid-based formulation of AmB, 
which remains the best choice for 
treating invasive mucormycosis (7). 
Posaconazole, a second-choice drug, 
has shown efficacy in CGD patients 
who had invasive mucormycosis re-
sistant to first-line treatment (8). Al-
logeneic donor–matched HSCT has 
a curative potential in CGD patients 
with refractory fungal infections (9). 
Several other authors have pointed 
to the emergence of rare new fungi 
in CGD, as well as reclassification 
of misdiagnosed fungi, identified by 
sequence-based analysis (10).
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To The Editor: Woodrats (Neo-
toma spp.) are natural hosts of White-
water Arroyo virus (WWAV) and other 
Tacaribe serocomplex viruses (family 
Arenaviridae) in the western United 
States and northern Mexico (1). The re-
sults of a previous study (2) suggested 
that WWAV or Tacaribe serocomplex 
viruses antigenically closely related to 
WWAV are etiologic agents of severe 
febrile illnesses in humans in the Unit-
ed States. We note that Junín virus and 
other South American Tacaribe sero-
complex viruses are etiologic agents of 
hemorrhagic fever in humans (3).
To further our knowledge of the 
epidemiology of the North American 
Tacaribe serocomplex viruses, we 
tested serum samples from hospital-
ized persons in a study of thrombo-
cytopenic febrile illnesses that mim-
icked hantavirus pulmonary syndrome 
for IgG against arenaviruses. The 173 
study participants were hospitalized 
during 1993–2001 in Arizona and New 
Mexico, United States. The study pro-
tocol was approved by the University 
of New Mexico Human Research Re-
view Committee and the Navajo Na-
tion Institutional Review Board. Ages 
of the study participants ranged from 9 
to 86 years (mean 40 years). Virtually 
all serum samples were acute-phase 
